Related Experiment Video
Updated: May 15, 2026

An R-Based Landscape Validation of a Competing Risk Model
Published on: September 16, 2022
Cost-effectiveness acceptability curves revisited
1Institute for Medical Technology Assessment, Erasmus University, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands. al@bmg.eur.nl
Abstract:
Since the introduction of the cost-effectiveness acceptability curve (CEAC) in 1994, its use as a method to describe uncertainty around incremental cost-effectiveness ratios (ICERs) has steadily increased. In this paper, first the construction and interpretation of the CEAC is explained, both in the context of modelling studies and in the context of cost-effectiveness (CE) studies alongside clinical trials. Additionally, this paper reviews the advantages and limitations of the CEAC. Many of the perceived limitations can be attributed to the practice of interpreting the CEAC as a decision rule while it was not developed as such. It is argued that the CEAC is still a useful tool in describing and quantifying uncertainty around the ICER, especially in combination with other tools such as plots on the CE plane and value-of-information analysis.
Related Concept Videos
Dose Response Curve: Conventional Versus Nonmonotonic
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Survival Curves
The Kaplan-Meier estimator is the most common method for constructing survival curves. This...
Bioequivalence Data: Statistical Interpretation
Pharmacokinetic Models: Comparison and Selection Criterion
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
